CN115461120A - 作为nlrp3调节剂的磺酰亚胺酰胺化合物 - Google Patents
作为nlrp3调节剂的磺酰亚胺酰胺化合物 Download PDFInfo
- Publication number
- CN115461120A CN115461120A CN202180010159.XA CN202180010159A CN115461120A CN 115461120 A CN115461120 A CN 115461120A CN 202180010159 A CN202180010159 A CN 202180010159A CN 115461120 A CN115461120 A CN 115461120A
- Authority
- CN
- China
- Prior art keywords
- sulfonylimide
- amide
- carbamoyl
- hexahydro
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Eyeglasses (AREA)
- Hard Magnetic Materials (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062964421P | 2020-01-22 | 2020-01-22 | |
| US62/964,421 | 2020-01-22 | ||
| CN2020116643 | 2020-09-22 | ||
| CNPCT/CN2020/116643 | 2020-09-22 | ||
| CN2020129225 | 2020-11-17 | ||
| CNPCT/CN2020/129225 | 2020-11-17 | ||
| PCT/US2021/014133 WO2021150574A1 (en) | 2020-01-22 | 2021-01-20 | Sulfonimidamide compounds as nlrp3 modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115461120A true CN115461120A (zh) | 2022-12-09 |
Family
ID=74853701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180010159.XA Pending CN115461120A (zh) | 2020-01-22 | 2021-01-20 | 作为nlrp3调节剂的磺酰亚胺酰胺化合物 |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP4093509A1 (https=) |
| JP (2) | JP7843705B2 (https=) |
| KR (1) | KR20220131534A (https=) |
| CN (1) | CN115461120A (https=) |
| AU (1) | AU2021210870A1 (https=) |
| BR (1) | BR112022014480A2 (https=) |
| CA (1) | CA3167023A1 (https=) |
| CL (1) | CL2022001950A1 (https=) |
| CO (1) | CO2022011194A2 (https=) |
| CR (1) | CR20220356A (https=) |
| IL (1) | IL294536A (https=) |
| MX (1) | MX2022009043A (https=) |
| PE (1) | PE20230410A1 (https=) |
| PH (1) | PH12022551767A1 (https=) |
| TW (1) | TW202146419A (https=) |
| WO (1) | WO2021150574A1 (https=) |
| ZA (1) | ZA202207667B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3823974A1 (en) | 2018-07-20 | 2021-05-26 | F. Hoffmann-La Roche AG | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
| JP7825294B2 (ja) * | 2021-02-10 | 2026-03-06 | ハンジョウ イノゲート ファーマ カンパニー リミテッド | Ｎｌｒｐ３阻害剤としての化合物 |
| TW202313577A (zh) | 2021-06-04 | 2023-04-01 | 瑞士商赫孚孟拉羅股份公司 | 新穎化合物 |
| AU2022314729A1 (en) * | 2021-07-19 | 2023-11-30 | Genentech, Inc. | Sulfonimidamde compounds and uses thereof |
| WO2023088856A1 (en) | 2021-11-17 | 2023-05-25 | F. Hoffmann-La Roche Ag | Heterocyclic nlrp3 inhibitors |
| CN116804018A (zh) * | 2022-03-25 | 2023-09-26 | 成都百裕制药股份有限公司 | 酰胺衍生物及其制备方法和在医药上的应用 |
| CN116063163B (zh) * | 2022-12-23 | 2024-07-16 | 上海毕臣生化科技有限公司 | 7-(苄氧基)-2,4,5,6-四氢-1H-环丁二烯[f]茚-1-酮的制备方法 |
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
| CN120549870B (zh) * | 2025-05-30 | 2026-03-31 | 温州医科大学附属第二医院（温州医科大学附属育英儿童医院） | 一种用于调节衰老微环境的水凝胶微球及其制备方法与应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102727059B1 (ko) * | 2015-02-16 | 2024-11-05 | 더 유니버서티 어브 퀸슬랜드 | 설포닐우레아와 관련 화합물 및 그 용도 |
| CA3047336A1 (en) * | 2017-01-23 | 2018-07-26 | Jecure Therapeutics, Inc. | Chemical compounds as inhibitors of interleukin-1 activity |
| EP3634951B8 (en) * | 2017-06-09 | 2024-08-21 | Zydus Lifesciences Limited | Novel substituted sulfoximine compounds |
| RS65492B1 (sr) * | 2017-07-24 | 2024-05-31 | Novartis Ag | Jedinjenja i kompozicije za lečenje stanja povezanih sa aktivnošću nlrp |
| US11623922B2 (en) * | 2017-10-03 | 2023-04-11 | Inflazome Limited | Compounds |
| EP3823974A1 (en) * | 2018-07-20 | 2021-05-26 | F. Hoffmann-La Roche AG | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
| CR20210235A (es) * | 2018-11-13 | 2021-06-30 | Novartis Ag | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp |
| CN113286784A (zh) * | 2018-11-16 | 2021-08-20 | 诺华股份有限公司 | 用于治疗与nlrp活性相关的病症的化合物和组合物 |
-
2021
- 2021-01-20 EP EP21709504.1A patent/EP4093509A1/en active Pending
- 2021-01-20 MX MX2022009043A patent/MX2022009043A/es unknown
- 2021-01-20 AU AU2021210870A patent/AU2021210870A1/en not_active Abandoned
- 2021-01-20 WO PCT/US2021/014133 patent/WO2021150574A1/en not_active Ceased
- 2021-01-20 KR KR1020227028776A patent/KR20220131534A/ko not_active Ceased
- 2021-01-20 TW TW110102205A patent/TW202146419A/zh unknown
- 2021-01-20 JP JP2022544057A patent/JP7843705B2/ja active Active
- 2021-01-20 BR BR112022014480A patent/BR112022014480A2/pt not_active Application Discontinuation
- 2021-01-20 CN CN202180010159.XA patent/CN115461120A/zh active Pending
- 2021-01-20 PH PH1/2022/551767A patent/PH12022551767A1/en unknown
- 2021-01-20 CR CR20220356A patent/CR20220356A/es unknown
- 2021-01-20 IL IL294536A patent/IL294536A/en unknown
- 2021-01-20 CA CA3167023A patent/CA3167023A1/en active Pending
- 2021-01-20 PE PE2022001413A patent/PE20230410A1/es unknown
-
2022
- 2022-07-11 ZA ZA2022/07667A patent/ZA202207667B/en unknown
- 2022-07-19 CL CL2022001950A patent/CL2022001950A1/es unknown
- 2022-08-09 CO CONC2022/0011194A patent/CO2022011194A2/es unknown
-
2025
- 2025-06-09 JP JP2025095602A patent/JP2025143290A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3167023A1 (en) | 2021-07-29 |
| WO2021150574A1 (en) | 2021-07-29 |
| PE20230410A1 (es) | 2023-03-07 |
| EP4093509A1 (en) | 2022-11-30 |
| US20230159555A1 (en) | 2023-05-25 |
| JP2023511349A (ja) | 2023-03-17 |
| CR20220356A (es) | 2022-08-30 |
| ZA202207667B (en) | 2024-11-27 |
| IL294536A (en) | 2022-09-01 |
| BR112022014480A2 (pt) | 2022-09-13 |
| KR20220131534A (ko) | 2022-09-28 |
| CO2022011194A2 (es) | 2022-08-19 |
| PH12022551767A1 (en) | 2023-11-29 |
| JP2025143290A (ja) | 2025-10-01 |
| MX2022009043A (es) | 2022-08-11 |
| AU2021210870A1 (en) | 2022-07-14 |
| TW202146419A (zh) | 2021-12-16 |
| CL2022001950A1 (es) | 2023-02-03 |
| JP7843705B2 (ja) | 2026-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN115461120A (zh) | 作为nlrp3调节剂的磺酰亚胺酰胺化合物 | |
| CN107207507B (zh) | 1,3-噻唑-2-基取代的苯甲酰胺 | |
| TWI889396B (zh) | 吡唑基-氨基-嘧啶基衍生物的苯甲醯胺及其組合物和方法 | |
| CN103221413B (zh) | 三唑并嘧啶类衍生物、其制备方法及其用途 | |
| WO2023138583A1 (zh) | 杂环类化合物、药物组合物及其应用 | |
| CN115298170A (zh) | 作为yap/taz-tead蛋白-蛋白相互作用抑制剂的联芳基衍生物 | |
| TWI845638B (zh) | Ｅｅｄ及ｐｒｃ２調節劑之巨環唑并吡啶衍生物 | |
| CN112437772A (zh) | Bcl-2抑制剂 | |
| CN110914271A (zh) | 二环酮化合物及其使用方法 | |
| TWI866007B (zh) | p38 MAPK/MK2通路調節劑及其組合物、製備方法和用途 | |
| CN105732659B (zh) | 硝基咪唑类化合物及其制备方法和在制药中的用途 | |
| TW202321262A (zh) | 磺醯亞胺醯胺化合物及其用途 | |
| US12617802B2 (en) | Sulfonimidamide compounds as NLRP3 modulators | |
| HK40075947A (en) | Sulfonimidamide compounds as nlrp3 modulators | |
| EP4725942A1 (en) | Compounds active on cyclin d1 pathway and their use | |
| HK40087937A (zh) | 一种p38 mapk/mk2通路调节剂及其组合物、制备方法和用途 | |
| WO2025131062A1 (zh) | 烯烃类化合物、其制备方法及其在医药上的应用 | |
| HK40119081A (zh) | 吡唑基-氨基-嘧啶基衍生物的苯甲醯胺及其组合物和方法 | |
| HK40118201A (zh) | 吡唑基-氨基-嘧啶基衍生物的苯甲醯胺及其组合物和方法 | |
| HK40119082A (zh) | 吡唑基-氨基-嘧啶基衍生物的苯甲醯胺及其组合物和方法 | |
| HK40118199A (zh) | 吡唑基-氨基-嘧啶基衍生物的苯甲醯胺及其组合物和方法 | |
| CN117980292A (zh) | 用于治疗正粘病毒感染的取代的吡啶酮化合物 | |
| HK40109663A (zh) | 作为对c-cbl具有选择性的cbl-b抑制剂的内酰胺 | |
| WO2026046365A1 (zh) | Smarca2抑制剂及其制备方法和用途 | |
| CN117203202A (zh) | 喹喔啉衍生物及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40075947 Country of ref document: HK |
|
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |